EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Society for Immunotherapy of Cancer (SITC) consensus statement on essential biomarkers for immunotherapy clinical protocols

Tricia R Cottrell, Michael T Lotze, Alaa Ali, Carlo B Bifulco, Christian M Capitini, Laura Q M Chow, Anthony R Cillo, Deborah Collyar, Leslie Cope, Julie Stein Deutsch, Genia Dubrovsky, Sacha Gnjatic und 25 weitere

Journal for ImmunoTherapy of Cancer · 2025-03 · 13 (3) · e010928

DOI: 10.1136/jitc-2024-010928 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal for ImmunoTherapy of Cancer, online erschienen am 07.03.2025. Verfasst von Tricia R Cottrell und 36 weiteren Autor:innen. Beteiligte Einrichtung: Queen's University Sinclair Cancer Research Institute, Kingston, Ontario, Canada trc3@queensu.ca. Hauptthemen laut MEDLINE: Immunotherapy, Neoplasms, Biomarkers, Tumor. Die Arbeit wurde bisher 60-mal zitiert (Crossref) und nennt 302 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Immunotherapy of cancer is now an essential pillar of treatment for patients with many individual tumor types. Novel immune targets and technical advances are driving a rapid exploration of new treatment strategies incorporating immune agents in cancer clinical practice. Immunotherapies perturb a complex system of interactions among genomically unstable tumor cells, diverse cells within the tumor microenvironment including the systemic adaptive and innate immune cells. The drive to develop increasingly effective immunotherapy regimens is tempered by the risk of immune-related adverse events. Evidence-based biomarkers that measure the potential for therapeutic response and/or toxicity are critical to guide optimal patient care and contextualize the results of immunotherapy clinical trials. Responding to the lack of guidance on biomarker testing in early-phase immunotherapy clinical trials, we propose a definition and listing of essential biomarkers recommended for inclusion in all such protocols. These recommendations are based on consensus provided by the Society for Immunotherapy of Cancer (SITC) Clinical Immuno-Oncology Network (SCION) faculty with input from the SITC Pathology and Biomarker Committees and the Journal for ImmunoTherapy of Cancer readership. A consensus-based selection of essential biomarkers was conducted using a Delphi survey of SCION faculty. Regular updates to these recommendations are planned. The inaugural list of essential biomarkers includes complete blood count with differential to generate a neutrophil-to-lymphocyte ratio or systemic immune-inflammation index, serum lactate dehydrogenase and albumin, programmed death-ligand 1 immunohistochemistry, microsatellite stability assessment, and tumor mutational burden. Inclusion of these biomarkers across early-phase immunotherapy clinical trials will capture variation among trials, provide deeper insight into the novel and established therapies, and support improved patient selection and stratification for later-phase clinical trials.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ImmunotherapyNeoplasmsBiomarkers, TumorHumansClinical Protocols

Stichwörter der Autor:innen

BiomarkerDendriticImmunotherapyNeutrophilT cell

Substanzen

Biomarkers, Tumor

Autor:innen und Institutionen

  • Queen's University Sinclair Cancer Research Institute, Kingston, Ontario, Canada trc3@queensu.ca.
  • UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, USA.
  • Stem Cell Transplant and Cellular Immunotherapy Program, Georgetown Lombardi Comprehensive Cancer Center, Washington, DC, Washington, DC, USA.
  • Earle A. Chiles Research Institute, Providence Cancer Institute, Portland, Oregon, USA.
  • University of Wisconsin School of Medicine and Public Health and Carbone Cancer Center, Madison, Wisconsin, USA.
  • The University of Texas at Austin, Austin, Texas, USA.

Förderung

  • NCI NIH HHS

Zitieren

APA

Cottrell, T. R., Lotze, M. T., Ali, A., Bifulco, C. B., Capitini, C. M., Chow, L. Q. M., Cillo, A. R., Collyar, D., Cope, L., Deutsch, J. S., Dubrovsky, G., Gnjatic, S., Goh, D., Halabi, S., Kohanbash, G., Maecker, H. T., Maleki Vareki, S., Mullin, S., Seliger, B., …, & Takimoto, C. H. (2025). Society for Immunotherapy of Cancer (SITC) consensus statement on essential biomarkers for immunotherapy clinical protocols. Journal for ImmunoTherapy of Cancer, 13(3), e010928. https://doi.org/10.1136/jitc-2024-010928

Vancouver

Cottrell TR, Lotze MT, Ali A, Bifulco CB, Capitini CM, Chow LQM, et al. Society for Immunotherapy of Cancer (SITC) consensus statement on essential biomarkers for immunotherapy clinical protocols. Journal for ImmunoTherapy of Cancer. 2025;13(3):e010928. doi:10.1136/jitc-2024-010928

BibTeX
@article{Cottrell2025,
  author = {Cottrell, Tricia R and Lotze, Michael T and Ali, Alaa and Bifulco, Carlo B and Capitini, Christian M and Chow, Laura Q M and Cillo, Anthony R and Collyar, Deborah and Cope, Leslie and Deutsch, Julie Stein and Dubrovsky, Genia and Gnjatic, Sacha and Goh, Denise and Halabi, Susan and Kohanbash, Gary and Maecker, Holden T and Maleki Vareki, Saman and Mullin, Sarah and Seliger, Barbara and Taube, Janis and Vos, Wim and Yeong, Joe and Anderson, Kristin G and Bruno, Tullia C and Chiuzan, Codruta and Diaz-Padilla, Ivan and Garrett-Mayer, Elizabeth and Glitza Oliva, Isabella C and Grandi, Paola and Hill, Elizabeth G and Hobbs, Brian P and Najjar, Yana G and Pettit Nassi, Phyllis and Simons, Virgil H and Subudhi, Sumit K and Sullivan, Ryan J and Takimoto, Chris H},
  title = {Society for Immunotherapy of Cancer (SITC) consensus statement on essential biomarkers for immunotherapy clinical protocols},
  journal = {Journal for ImmunoTherapy of Cancer},
  year = {2025},
  volume = {13},
  number = {3},
  pages = {e010928},
  doi = {10.1136/jitc-2024-010928}
}
Kostenlos starten →